Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/58455
Registro completo de metadados
Campo DCValorIdioma
dc.creatorTavares, Laísa Macedo-
dc.creatorJesus, Luís Cláudio Lima de-
dc.creatorBatista, Viviane Lima-
dc.creatorBarroso, Fernanda Alvarenga Lima-
dc.creatorFreitas, Andria dos Santos-
dc.creatorCampos, Gabriela Munis-
dc.creatorAmérico, Monique Ferrary-
dc.creatorSilva, Tales Fernando da-
dc.creatorCoelho-Rocha, Nina Dias-
dc.creatorBelo, Giovanna Angeli-
dc.creatorDrumond, Mariana Martins-
dc.creatorMancha-Agresti, Pamela-
dc.creatorVital, Kátia Duarte-
dc.creatorFernandes, Simone Odília Antunes-
dc.creatorCardoso, Valbert Nascimento-
dc.creatorBirbrair, Alexander-
dc.creatorFerreira, Enio-
dc.creatorMartins, Flaviano Santos-
dc.creatorLaguna, Juliana Guimarães-
dc.creatorAzevedo, Vasco-
dc.date.accessioned2023-10-24T15:47:45Z-
dc.date.available2023-10-24T15:47:45Z-
dc.date.issued2023-
dc.identifier.citationTAVARES, L. M. et al. Synergistic synbiotic containing fructooligosaccharides and Lactobacillus delbrueckii CIDCA 133 alleviates chemotherapy-induced intestinal mucositis in mice. World Journal of Microbiology and Biotechnology, [S.l.], v. 39, 2023.pt_BR
dc.identifier.urihttps://link.springer.com/article/10.1007/s11274-023-03679-0pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/58455-
dc.description.abstractIntestinal mucositis is a commonly reported side effect in oncology patients undergoing chemotherapy and radiotherapy. Probiotics, prebiotics, and synbiotics have been investigated as alternative therapeutic approaches against intestinal mucositis due to their well-known anti-inflammatory properties and health benefits to the host. Previous studies showed that the potential probiotic Lactobacillus delbrueckii CIDCA 133 and the prebiotic Fructooligosaccharides (FOS) alleviated the 5-Fluorouracil (5-FU) chemotherapy-induced intestinal mucosa damage. Based on these previous beneficial effects, this work evaluated the anti-inflammatory property of the synbiotic formulation containing L. delbrueckii CIDCA 133 and FOS in mice intestinal mucosa inflammation induced by 5-FU. This work showed that the synbiotic formulation was able to modulate inflammatory parameters, including reduction of cellular inflammatory infiltration, gene expression downregulation of Tlr2, Nfkb1, and Tnf, and upregulation of the immunoregulatory Il10 cytokine, thus protecting the intestinal mucosa from epithelial damage caused by the 5-FU. The synbiotic also improved the epithelial barrier function by upregulating mRNA transcript levels of the short chain fatty acid (SCFA)-associated GPR43 receptor and the occludin tight junction protein, with the subsequent reduction of paracellular intestinal permeability. The data obtained showed that this synbiotic formulation could be a promising adjuvant treatment to be explored against inflammatory damage caused by 5-FU chemotherapy.pt_BR
dc.languageen_USpt_BR
dc.publisherSpringerpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceWorld Journal of Microbiology and Biotechnologypt_BR
dc.subjectChemotherapypt_BR
dc.subjectIntestinal damagept_BR
dc.subjectSynbioticpt_BR
dc.subjectImmunomodulationpt_BR
dc.subjectIntestinal barrierpt_BR
dc.titleSynergistic synbiotic containing fructooligosaccharides and Lactobacillus delbrueckii CIDCA 133 alleviates chemotherapy-induced intestinal mucositis in micept_BR
dc.typeArtigopt_BR
Aparece nas coleções:DMV - Artigos publicados em periódicos

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.